# OnCo record paper-swog-s1826-nivolumab-avd-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-swog-s1826-nivolumab-avd-nejm-2024" ;
  schema:name "SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults"@en ;
  schema:description "Adding a PD-1 antibody to chemotherapy beat the brentuximab-based standard, with 92% of patients progression-free at two years and less nerve damage."@en ;
  schema:url <https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2405888>, <https://clinicaltrials.gov/study/NCT03907488> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2405888> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Herrera AF, LeBlanc M, Castellino SM, et al." ;
  onco:related <https://onco.cc/pairings/pd1-plus-avd-hodgkin/>, <https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/> ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/cd30/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:companies <https://onco.cc/companies/bms/>, <https://onco.cc/companies/swog/>, <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/trials/echelon-1/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/ahod2131/> ;
  onco:people <https://onco.cc/people/alex-herrera/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-survivorship/> ;
  onco:journals <https://onco.cc/journals/nejm/> .